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Power calculations were not undertaken. 95 patients were recruited, 1 patient proved to have Dukes' A and was excluded, and therefore 94 were included. 21 patients (24%) failed to return the questionnaire, but no significant difference was detected between these patients and those who responded with respect to age, sex, tumor location, Dukes' stage or treatment modality (apparently 1 of the deceased patients either responded or failed to return the questionnaire).
Study design
This was a single-centre randomised controlled trial (RCT). Patients were followed for a median of 16 months (range: 0-37 months); 82 (87%) were still alive at follow-up, 62 (76%) patients responded to the questionnaire, all of the questions were answered by all but two of the patients, who had not marked their scores in the simple QoL scale. No information was provided on the randomisation method.
Analysis of effectiveness
The analysis was based on available data from completers only, as described above. The primary health outcome was QoL (EuroQol, a simple QoL scale and the global QoL measure of the EORTC QLQ-C 30).
Effectiveness results
No significant differences in QoL (combining all 3 QoL assessments) were revealed between the follow-up and adjuvant chemotherapy group and there were no differences between withdrawals and the others, neither did follow-up time influence the QoL. The median QoL in all patients and measures was 0.83 (0-1 scale).
Clinical conclusions
Adjuvant chemotherapy does not affect short-term QoL.
Modelling
No modelling was undertaken.
Measure of benefits used in the economic analysis
Quality Adjusted Life Years (QALYs) were used. Life expectancy in Norway at age 62 is 19.6 years; and with radical surgery this patient has a 0.53 probability of a 5-year survival and a 0.47 probability of living less than 5 years. The authors assumed that if the patient survives 5 years, he/she will go on to live for the number of years of their normal expectancy with no relapse (19.6 years). Thus the life expectancy of a patient undergoing surgery is calculated as 12.8 ((0.53x19.6)+(0.47x5)). The quality weight was derived from the mean QoL in all patients and measures in this study.
Direct costs
Direct costs included cost of hospital stay and costs of chemotherapy. The cost of hospital stay was based on 1995 annual accounts of the Departments of Surgery (234 per patient per day)) and Oncology (219 per patient per day), medication costs were calculated separately. The total account of the two departments included four areas of costs: staff costs, overheads, consumables and capital. The median hospital stay of patients treated at the Department of Surgery was used for all patients when calculating the total costs of hospitalisation. The cost of chemotherapy was based on the 1995 UHT pharmacy costs. The cost of chemotherapy was 2,188 per patient for 12 months, which includes pharmacy administration costs. The cost of chemotherapy administration in an outpatient setting was calculated according to the tariff of the Norwegian Medical Association (768 per patient per year). In a sensitivity analysis three different discount rates were used: 0%, 5% and 10%.
